---
schema_version: "secwatch.filing_event.v1"
accession: "0001672688-26-000047"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:46:50.830932+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Absci appoints Ransi Somaratne as CMO; Chief Innovation Officer Andreas Busch to retire

## Summary
- Ransi Somaratne, formerly SVP Clinical Development at Vertex, appointed CMO effective March 3, 2026.
- Andreas Busch, Chief Innovation Officer, will retire March 31, 2026 and serve as scientific advisor for 2 years.
- Busch receives $25,500 annual retainer plus grants of 22,800 stock options and 5,800 RSUs under the 2021 Plan.
- Busch's vested options (2,489,290 shares) extended up to 3 months post-advisory termination; unvested options cancelled.
- Amended director and officer indemnification agreements adopted March 6, 2026, enhancing change-in-control and good faith provisions.

## SEC filing metadata
- accession: 0001672688-26-000047
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000047/0001672688-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000047/absc-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001672688-26-000047
- JSON: https://secwatch.observer/filing/0001672688-26-000047.json
- Plain text: https://secwatch.observer/filing/0001672688-26-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.